A Phase III, randomized, multi-site, open-label trial of BNT323/DB-1303 versus investigator s choice of chemotherapy in previously treated patients with HER2-expressing recurrent endometrial cancer

15383BNT323-01-GOG-3105OpenA Phase III, randomized, multi-site, open-label trial of BNT323/DB-1303 versus investigator s choice of chemotherapy in previously treated patients with HER2-expressing recurrent endometrial cancerBNT323-01 (GOG-3105)NCT06340568IndustrialAdultTreatmentIIIGlobalOtherHoskins, EbonyMedStar Health and GUMC; Medstar Washington Hospital Center : Reva PersaudGyn. Onc.Oncology GroupMHRI Washington Cancer Institute17525Reva PersaudReva PersaudReva.S.Persaud@medstar.net2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>